Endothelial progenitor cells purchase
Ended Purchase Order Awarded
- Contract number
- 75N95021P00318
- Awardee
-
Stembiosys Inc. UEI QNQQJ5K2KXG9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $66,844
Award facts
- Opportunity
-
- Endothelial Progenitor Cells Purchase Solicitation · 75N95021Q00252 · Posted Jun 22, 2021
- Contract value 100% obligated
- $66,844.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Antonio, TX 78229, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract 75N95021P00318?
75N95021P00318 was awarded to Stembiosys Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 29, 2021.
How much is contract 75N95021P00318 worth?
The government has obligated $66,844 on 75N95021P00318.
Which agency awarded contract 75N95021P00318?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95021P00318, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95021P00318 competed?
The extent of competition for 75N95021P00318 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award